"The EPA's approval of BioNeutral's Ygiene™ disinfectant is very welcome news," said Dr. Philip Tierno, Jr., PhD, Director of Clinical Microbiology & Immunology at New York University Langone Medical Center and Clinical Professor of Microbiology & Pathology at New York University School of Medicine. "Ygiene™ will now give hospitals a far more powerful, yet much safer alternative to bleach, and to fight the ever increasing array of super-bugs in their environment."
"We are all extremely pleased," stated Dr. Andy Kielbania, Chief Scientist at BioNeutral Group, "This EPA approval is a milestone in the validation of our Ygiene™ technology and all of the various product lines it encompasses. We are now extremely well positioned to proceed with vigor in making both of our complementary platforms Ogiene™ and Ygiene™ products available to all."
"The EPA's approval of our antimicrobial technology comes at an extremely fortuitous time in the Company's development as we gain positive momentum first in Kentucky, under the direction of our services division CEO Frank Battafarano, and then beyond," said Stephen J. Browand Chairman, President and CEO of BioNeutral Group, Inc. "Having new and innovative tools for reducing and eliminating hospital acquired infections is more important than ever and we are proud to be contributing to this effort in such a meaningful way. BioNeutral is committed to ensuring that our game changing products get into the hands of the people and institutions that can bring about a much needed positive change to healthcare systems in this country and abroad."
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes ha
|SOURCE BioNeutral Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved